Huons, a subsidiary of Huons Global, said Tuesday that it has acquired a patent for a compact formulation for oral administration form of clarithromycin, a macrolide antibiotic used to treat various conditions.
The patent named “composition and preparation method of tablets containing clarithromycin,” relates to a technology for reducing the number of excipients compared to conventional tablets by about one-third, thereby substantially reducing the size of tablets.
Until now, due to the drug’s nature which is highly viscous and less compressible, it needed additional excipient to produce as the main ingredient may adhere to the production equipment during the formulation process, which may often cause a problem of the content of the drug. Such process led to increasing the size of the tablet, which caused discomfort when taking the tablet and lowered its compliance.
Huons’ continued research and development have found the optimum mixing ratio with excipients suitable for the clarification process of clarithromycin. The company is currently using the technology on its Clithro tablet, an anti-bacterial agent, to provide patients with products that are smaller compared to other similar products.
“The patent has a great significance in that it improves the compliance of the drug efficacy and solves the inconvenience of patients,” said Oh Joon-gyo, head of Huons’ department of discovery. “The company plans to utilize this patented technology and apply it to the miniaturization of other big-tablet products.”
<© Korea Biomedical Review, All rights reserved.>